<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abstract Introduction: Anti-cancerous effects of cyclooxygenase-2 (COX-2) inhibitors have been reported in different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>High expression of COX-2 has been demonstrated in various <z:hpo ids='HP_0002664'>neoplasms</z:hpo> such as colorectal, gastric, esophageal, breast, <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancers</z:e>, and <z:mpath ids='MPATH_481'>pre-neoplastic lesions</z:mpath> such as colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Goal: The purpose of this study was to investigate percentage of positive COX-2 expression in <z:hpo ids='HP_0008069'>skin tumors</z:hpo>, including pre-malignant and <z:mp ids='MP_0002018'>malignant tumors</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Methods: This is an analytic cross-sectional study that includes 62 skin <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples, among which 49 samples were malignant and 13 were pre-malignant </plain></SENT>
<SENT sid="4" pm="."><plain>After study for determination of pathologic kind of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, samples underwent immunohistochemical study for COX-2 expression </plain></SENT>
<SENT sid="5" pm="."><plain>The DakoCytomation EnVision+System-HRP is a two-step extremely sensitive IHC staining technique which we used in this study </plain></SENT>
<SENT sid="6" pm="."><plain>Results: Among the <z:hpo ids='HP_0008069'>skin tumors</z:hpo>, a considerable number of COX-2 expression were found in <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> (<z:mp ids='MP_0004207'>SCC</z:mp>) (16 of 17; 94%), <z:hpo ids='HP_0002671'>basal cell carcinomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>) (28 of 32; 87.5%), <z:e sem="disease" ids="C0006079" disease_type="Neoplastic Process" abbrv="">Bowen's disease</z:e> (BD) (8 of 9; 89%), and <z:mpath ids='MPATH_151'>actinic keratosis</z:mpath> (AK) (4 of 4; 100%) </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusion: COX-2 expression was positive in <z:hpo ids='HP_0008069'>skin tumors</z:hpo> including malignant and pre-malignant <z:mp ids='MP_0001212'>skin lesions</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>This study strongly suggests that COX-2 can be one of the molecular targets in treating various <z:hpo ids='HP_0008069'>skin tumors</z:hpo> </plain></SENT>
</text></document>